InsidersTradesSigma
Track the AMOEBA share price and the full insider trade history of the company, a listed issuer based in France. Shares trade on the FR market, under the supervision of AMF. Operating in the Healthcare & Pharma sector, AMOEBA has recorded 91 reports. Market capitalisation: €51.3m. The latest transaction was filed on 3 July 2026 (Cession). Among the most active insiders: Benoit Villers. All data is accessible without an account.
91
Insider Decl.
n/a
Thresholds
€431,697
79 ops.
Buy Volume
€120,789
6 ops.
Sell Volume
44Σ signal
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 3 July 2026
Declarations91 total
31,100 shares@ €0.85080.039% mcap100.0% of flowActionEuronext Growth ParisISIN FR00110515982026DD1124598
40,000 shares0ActionHors plateforme de négociationISIN FR00110515982025DD1038995
Canonical exit: 24 Jul 2025 (T+90)
560,000 shares0ActionHors plateforme de négociationISIN FR00110515982025DD1038830
Canonical exit: 24 Jul 2025 (T+90)
1,200,000 shares0ActionHors plateforme de négociationISIN FR00110515982025DD1038852
Canonical exit: 24 Jul 2025 (T+90)
3,035 shares@ €0.828614.5% of flowActionEuronext Growth ParisISIN FR00110515982025DD1024259
Canonical exit: 4 Jun 2025 (T+90)
2,700 shares@ €0.89514.0% of flowActionEuronext Growth ParisISIN FR00110515982025DD1018494
Canonical exit: 4 May 2025 (T+90)
300 shares@ €0.68670.1% of flowActionEuronext Growth ParisISIN FR00110515982024DD1004987
Canonical exit: 6 Feb 2025 (T+90)
1,100 shares@ €0.7050.2% of flowActionEuronext Growth ParisISIN FR00110515982024DD1004742
Canonical exit: 5 Feb 2025 (T+90)
4,600 shares@ €0.62450.8% of flowActionEuronext Growth ParisISIN FR00110515982024DD1004259
Canonical exit: 3 Feb 2025 (T+90)
400 shares@ €0.6220.1% of flowActionEuronext Growth ParisISIN FR00110515982024DD1003845
Canonical exit: 2 Feb 2025 (T+90)
2,800 shares@ €0.61080.5% of flowActionEuronext Growth ParisISIN FR00110515982024DD1003442
Canonical exit: 27 Jan 2025 (T+90)
980 shares@ €0.5863.3% of flowActionEuronext Growth ParisISIN FR00110515982024DD1003074
Canonical exit: 28 Jan 2025 (T+90)
200 shares@ €0.5880.0% of flowActionEuronext Growth ParisISIN FR00110515982024DD1002386
Canonical exit: 23 Jan 2025 (T+90)
6,602 shares@ €0.55351.0% of flowActionEuronext Growth ParisISIN FR00110515982024DD1002282
Canonical exit: 22 Jan 2025 (T+90)
9,757 shares@ €0.56281.5% of flowActionEuronext Growth ParisISIN FR00110515982024DD1001954
Canonical exit: 21 Jan 2025 (T+90)
4,600 shares@ €0.5250.7% of flowActionEuronext Growth ParisISIN FR00110515982024DD1001719
Canonical exit: 20 Jan 2025 (T+90)
1,312 shares@ €0.52590.2% of flowActionEuronext Growth ParisISIN FR00110515982024DD1001524
Canonical exit: 19 Jan 2025 (T+90)
1,100 shares@ €0.55860.2% of flowActionEuronext Growth ParisISIN FR00110515982024DD1000301
Canonical exit: 9 Jan 2025 (T+90)
10,985 shares@ €0.55481.7% of flowActionEuronext Growth ParisISIN FR00110515982024DD1000141
Canonical exit: 7 Jan 2025 (T+90)
5,764 shares@ €0.52330.8% of flowActionEuronext Growth ParisISIN FR00110515982024DD999735
Canonical exit: 6 Jan 2025 (T+90)
51,705 shares@ €0.51997.5% of flowActionEuronext Growth ParisISIN FR00110515982024DD999586
Canonical exit: 6 Jan 2025 (T+90)
6,300 shares@ €0.57320.8% of flowActionEuronext Growth ParisISIN FR00110515982024DD993153
Canonical exit: 28 Nov 2024 (T+90)
5,500 shares@ €0.64820.6% of flowActionEuronext Growth ParisISIN FR00110515982024DD993154
3,200 shares@ €0.55690.5% of flowActionEuronext Growth ParisISIN FR00110515982024DD992919
Canonical exit: 26 Nov 2024 (T+90)
20,049 shares@ €0.56023.1% of flowActionEuronext Growth ParisISIN FR00110515982024DD992774
Canonical exit: 25 Nov 2024 (T+90)
25 of 91 declarations
关于 AMOEBA
Amoéba 是一家法国绿色科技公司，在泛欧交易所增长板上市，股票代码为 ALMIB，ISIN 为 FR0011051598。该公司成立于 2010 年，总部位于里昂附近的沙西厄，其战略围绕一个专有平台构建，该平台基于对天然存在的 Willaertia magna C2c Maky 变形虫的工业应用。其使命是开发天然微生物解决方案，旨在减少生物技术、作物保护和化妆品等多个高潜力终端市场的微生物风险。该公司最初通过一种用于水处理的生物杀菌剂获得认可，随后逐渐将其范围扩展到农业生物防治和化妆品成分。 从历史上看，Amoéba 因其开发大规模培养变形虫的工业工艺的能力而闻名，该公司称这种能力在全球独一无二。该公司于 2015 年上市，并在研发和商业化前开发方面投入了多年。自 2023-2025 年以来，随着其战略转向具有最佳价值创造潜力和最短变现时间的市场，其形象也随之演变。此次重新定位伴随着 2024 年初的治理变革，Benoit Villers 被任命为董事长，并明确了加速实现正向经营现金流的目标。 Amoéba 的主要业务线现在是农业生物防治和化妆品，两者都建立在基于变形虫裂解物的相同核心技术之上。从监管角度来看，该公司已取得了几个重要的里程碑：其活性物质在美国获得批准，欧洲食品安全局 (EFSA) 在欧洲给出最终积极意见，随后欧盟委员会于 2025 年 6 月最终批准了该活性物质，以及其 AXPERA 产品于 2025 年 10 月获得美国市场授权。2026 年初，Amoéba 还宣布了与 Koppert 的首个商业订单，这标志着从开发到商业化的明确一步。 从地理上看，Amoéba 仍然牢牢扎根于法国，其总部和生产基地位于沙西厄，但其商业战略是国际化的。该公司主要将欧洲和美国作为其最初的上市市场，并表示它依赖分销合作伙伴来支持商业化。它被定位为一个利基创新驱动型参与者，具有漫长的监管周期，但具有强大的差异化特征、强大的知识产权和引人注目的替代传统化学解决方案的叙述。2025 年和 2026 年的近期增资旨在为工业和商业规模化提供资金。
